ATAI ATAI LIFE SCIENCES BV

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation:

Format: Fireside chat and 1x1 investor meetings

Date and Time: Fireside chat on Monday, March 3 at 11:50 A.M. ET

Webcast link:

An archived replay will be available on the Investors section of the atai website under for up to 90 days.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. The Company was founded in response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to developing novel, evidence-based therapeutics to treat depression, anxiety and other mental health disorders. atai's vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit .

Contact Information

Investor Contact:

Media Contact:



EN
24/02/2025

Underlying

ATAIATAI LIFE SCIENCES BV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ATAI LIFE SCIENCES BV

 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Reports First Quarter 2025 Financial Results and Re...

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment-resistant depression (TRD) - the largest controlled trial of mebufotenin and the first and only such trial to investigate mebufotenin in the U.S.Dosed the first patient in the exploratory Phase 2 study of EMP-01 (oral R-MDMA) for the treatment of ...

2h / 43m 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of E...

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo-controlled Phase 2 study will assess the safety, tolerability and efficacy of EMP-01 in adults with social anxiety disorder - Topline data anticipated in the first quarter of 2026 NEW YORK and BERLIN, May 13, 2025 (GLOBE...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial...

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights  - Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipate...

March 17, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase...

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression - Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being developed as a rapid-acting, robust and durable antidepressant for people suffering from treatment-resistant depression, which affects approximately 100 million people globally - VLS-01 is designed to fit ...

March 11, 2025 1 EN
 PRESS RELEASE
Free
ATAI ATAI LIFE SCIEN...

atai Life Sciences Announces Completion of Enrollment in Phase 2b Clin...

atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression - The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (mebufotenin benzoate) in patients with treatment-resistant depression - The open-label extension stage of the Phase 2b clinical trial continues to enroll patients to evaluate the safety and efficacy of a second dose of BPL-003 - As previously reported, the Phase 2a study of BPL-003 in patients with ...

March 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch